RWRuoheng Wei

Ruoheng Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruoheng Wei has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

    by Shan Pan, Teresa Tsakok, Ruoheng Wei, Nick Dand, Floris C. Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Angela Pushpa‐Rajah, et al.

    Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.